Literature DB >> 9180183

Seroepidemiology of emerging tickborne infectious diseases in a Northern California community.

C L Fritz1, A M Kjemtrup, P A Conrad, G R Flores, G L Campbell, M E Schriefer, D Gallo, D J Vugia.   

Abstract

A seroprevalence and risk factor study of emerging tickborne infectious diseases (Lyme disease, ehrlichiosis, and babesiosis) was conducted among 230 residents of a semirural community in Sonoma County, California. Over 50% of residents reported finding a tick on themselves in the preceding 12 months. Samples from 51(23%) residents were seroreactive to antigens from one or more tickborne disease agents: 1.4% to Borrelia burgdorferi, 0.4% to Ehrlichia equi, 4.6% to Ehrlichia chaffeensis, and 17.8% to the Babesia-like piroplasm WA1. Only 14 (27%) of these seroreactive residents reported one or more symptoms compatible with these diseases. Seroreactivity was significantly associated with younger age (<16 years), longer residence in the community (11-20 years), and having had a physician's diagnosis of Lyme disease. In northern California, the risk of infection with these emerging tickborne diseases, particularly in children, may be greater than previously recognized.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180183     DOI: 10.1086/516476

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Two tick-borne diseases in one: a case report of concurrent babesiosis and Lyme disease in Ontario.

Authors:  C C dos Santos; K C Kain
Journal:  CMAJ       Date:  1999-06-29       Impact factor: 8.262

Review 2.  Transfusion-transmitted Babesia spp.: bull's-eye on Babesia microti.

Authors:  David A Leiby
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 3.  Chronic coinfections in patients diagnosed with chronic lyme disease: a systematic review.

Authors:  Paul M Lantos; Gary P Wormser
Journal:  Am J Med       Date:  2014-06-12       Impact factor: 4.965

4.  Comparison of the Babesia duncani (WA1) IgG detection rates among clinical sera submitted to a reference laboratory for WA1 IgG testing and blood donor specimens from diverse geographic areas of the United States.

Authors:  Harry E Prince; Mary Lapé-Nixon; Hemlata Patel; Cindy Yeh
Journal:  Clin Vaccine Immunol       Date:  2010-09-22

5.  Dusky-footed wood rats (Neotoma fuscipes) as reservoirs of granulocytic Ehrlichiae (Rickettsiales: Ehrlichieae) in northern California.

Authors:  W L Nicholson; M B Castro; V L Kramer; J W Sumner; J E Childs
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

6.  Serologic testing for human granulocytic ehrlichiosis at a national referral center.

Authors:  J A Comer; W L Nicholson; J G Olson; J E Childs
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

7.  Immunodiagnosis of human granulocytic ehrlichiosis by using culture-derived human isolates.

Authors:  M D Ravyn; J L Goodman; C B Kodner; D K Westad; L A Coleman; S M Engstrom; C M Nelson; R C Johnson
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

8.  An Investigation of a Cluster of Parapoxvirus Cases in Missouri, Feb-May 2006: Epidemiologic, Clinical and Molecular Aspects.

Authors:  Edith R Lederman; Min Tao; Mary G Reynolds; Yu Li; Hui Zhao; Scott K Smith; Lisa Sitler; Dana L Haberling; Whitni Davidson; Christina Hutson; Ginny Emerson; David Schnurr; Russell Regnery; Bao-Ping Zhu; Howard Pue; Inger K Damon
Journal:  Animals (Basel)       Date:  2013-02-28       Impact factor: 2.752

9.  Ibuprofen-associated minimal change disease and acute interstitial nephritis with possibly linked membranous glomerulonephritis.

Authors:  Andrew C Liu; Yongen Chang; Jonathan E Zuckerman; Kamyar Kalantar-Zadeh; Lena M Ghobry; Ramy M Hanna
Journal:  SAGE Open Med Case Rep       Date:  2021-06-21

10.  Ehrlichia chaffeensis infections among HIV-infected patients in a human monocytic ehrlichiosis-endemic area.

Authors:  Thomas R Talbot; James A Comer; Karen C Bloch
Journal:  Emerg Infect Dis       Date:  2003-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.